Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Castanospermine SCHEMBL29356587 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL10471084 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL30094437 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL31666834 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL23845877 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL2434193 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL23689596 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL4645261 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL764545 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL13666292 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934688-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | University of Virginia Patent Foundation (US) | 2022-01-12 | — | — | EP | claimed |
| WO-2020185675-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-09-17 | — | — | WO | claimed |
| EP-0202661-B1 | ISOLATION OF CASTANOSPERMINE AND ITS USE AS AN ANTIDIABETIC AGENT | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0202661-A2 | Isolation of castanospermine and its use as an antidiabetic agent | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-11-26 | — | — | EP | claimed |
| EP-3934688-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | University of Virginia Patent Foundation (US) | 2022-01-12 | — | — | EP | disclosed |
| WO-2020185675-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020023390-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-1802327-A4 | COMBINATION ANTI-VIRAL COMPOSITIONS COMPRISING CASTANOSPERMINE AND METHODS OF USE | MIGENIX INC (CA) | 2009-07-15 | — | — | EP | disclosed |
| EP-1802327-A1 | COMBINATION ANTI-VIRAL COMPOSITIONS COMPRISING CASTANOSPERMINE AND METHODS OF USE | MIGENIX INC. (CA) | 2007-07-04 | — | — | EP | disclosed |
| EP-1789043-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPADNAVIRIDAE INFECTION | MIGENIX INC. (CA) | 2007-05-30 | — | — | EP | disclosed |
| US-5229523-A | Glycosidase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-07-20 | — | — | US | disclosed |
| WO-1992021655-A2 | 2-METHYL-5-HYDROXYMETHYL- AND 2,5-DIMETHYL-3,4-DIHYDROXYPYRROLIDINES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0430983-A4 | USE OF CASTANOSPERMINE AS AN ANTI-INFLAMMATORY AND IMMUNOSUPPRESSANT AGENT | — | 1992-08-26 | — | — | EP | disclosed |
| EP-0430983-A1 | USE OF CASTANOSPERMINE AS AN ANTI-INFLAMMATORY AND IMMUNOSUPPRESSANT AGENT. | UNIV AUSTRALIAN (AU) | 1991-06-12 | — | — | EP | disclosed |
| EP-0416011-A4 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | US COMMERCE (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | disclosed |
| WO-1990001319-A1 | USE OF CASTANOSPERMINE AS AN ANTI-INFLAMMATORY AND IMMUNOSUPPRESSANT AGENT | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1990-02-22 | — | — | WO | disclosed |
| EP-0295538-A2 | Inhibitors of glycoprotein processing having anti retroviral activity | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | GAA 1/4885MEN1 3811/4885CYP1A2 3704/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | GAA 107/4885MEN1 3268/4885CYP1A2 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.